Last reviewed · How we verify

NCT05690412: PaNETh

Efficacy and Safety of Endoscopic Papillectomy in the Treatment of Ampullary Neoplasms.

Status unknown Last updated 23 January 2023
What this trial tests

trial testing Endoscopic Papillectomy in Ampullary Adenoma in 400 participants. Status unknown.

Timeline
1 April 2022
Primary endpoint
31 March 2023
31 March 2023

Quick facts

Lead sponsorAzienda Unità Sanitaria Locale della Romagna
StatusStatus unknown
Study typeOBSERVATIONAL
Enrollment400
Start date1 April 2022
Primary completion31 March 2023
Estimated completion31 March 2023
Sites1 location across Italy

Drugs / interventions tested

Conditions studied

Sponsor

Azienda Unità Sanitaria Locale della Romagna

Who can join

18 and older, any sex, with Ampullary Adenoma or Ampulla of Vater Adenoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The aim of our study is to provide data on the efficacy and safety of endoscopic papillectomy, by including consecutive patients treated after 2015, when first guidelines on endoscopic management of ampullary neoplasms were available.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Endoscopic Papillectomy

Trials testing the same drug.

Other recruiting trials for Ampullary Adenoma

Currently open trials in the same condition.

Other Azienda Unità Sanitaria Locale della Romagna trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05690412.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing